Navigation Links
Life Technologies Develops Potent Drug Delivery Technology for Therapeutics Market
Date:7/14/2011

CARLSBAD, Calif., July 14, 2011 /PRNewswire/ -- Life Technologies Corporation today announced that it has developed new drug delivery technology specially designed for therapeutic applications that is 100-fold more potent than previous formulations. The technology is available for licensing as part of a new out-licensing program.

Scientists at Life Technologies have developed the novel proprietary siRNA delivery reagents by using new lipid molecules and formulation design to drastically improve potency and minimize toxicity in vivo. A single dose of 12.5ug siRNA per kilogram can achieve 50 percent knock down of a target gene, said Keith Farnsworth, product management leader at Life Technologies.

"Historically, delivery of siRNA has been problematic due to the high risk of toxicity and hampered efficiency," he said. "Life Technologies' new formulations provide the pharmaceutical and biotech industries a viable platform to help develop siRNA drugs that overcome these challenges."

The availability of the new formulations follows Life Technologies' 2010 launch of Invivofectamine 2.0®, a lipid-based siRNA delivery technology for the research market that can knock down up to four genes in vivo in lab models for extended periods with a single application. The novel formulations available through the out-licensing program use different molecules that make it ideal for therapeutic applications.

For more information, contact Maya Tanaka, Sr. Manager, Business Development and Licensing, (760) 268-7982; Maya.Tanaka@lifetech.com

About Life Technologies (www.lifetechnologies.com)

Life Technologies Corporation is a global biotechnology company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific and medical advancements that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance the fields of discovery and translational research, molecular medicine, stem cell-based therapies, food safety and animal health, and 21st century forensics. The company manufactures both molecular diagnostic and research use only products. Life Technologies' industry-leading brands are found in nearly every life sciences lab in the world and include innovative instrument systems under the Applied Biosystems and Ion Torrent names, as well as, the broadest range of reagents with its Invitrogen, GIBCO, Ambion, Molecular Probes and TaqMan® products. Life Technologies had sales of $3.6 billion in 2010, has a workforce of approximately 11,000 people, has a presence in approximately 160 countries, and possesses one of the largest intellectual property estates in the life sciences industry, with approximately 3,900 patents and exclusive licenses. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

Life Technologies' Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

(Logo:  http://photos.prnewswire.com/prnh/20110216/MM49339LOGO)

Life Technologies Contact
Mauricio Minotta
760-929-2456
Mauricio.minotta@lifetech.com


'/>"/>
SOURCE Life Technologies Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Double Eagle Holdings Enters Into Supply Agreement with Platform Delivery Technologies Inc.
2. IDEV Technologies Launches Lower Profile SUPERA VERITAS® Stent Delivery System
3. Life Technologies Sets 2nd Quarter 2011 Earnings Release Date for Thursday, July 28, 2011
4. Flow Cytometry: Products, Technologies and Global Markets
5. Micell Technologies Announces Reduced Clinical Trial Sample Size for MiStent® Drug-Eluting Coronary Stent Based on Early Clinical Data
6. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
7. Althea Technologies Receives FDA Approval to Initiate Commercial Manufacturing
8. Global Technologies, Ltd. Announces LOI to Acquire and Merge with Oxygen Orchard, Inc.
9. Alan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc.
10. Life Technologies Consortium to Create New Frontline Diagnostic Utilising DNA Sequencing for Cancer Patients in the U.K.
11. China Medical Technologies Announces Strategic Collaboration Between its Subsidiary, GP Medical, and Da An Health
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
(Date:6/23/2016)... June 23, 2016  MedSource announced today that ... e-clinical software solution of choice.  This latest decision ... value to their clients by offering a state-of-the-art ... relationship establishes nowEDC as the EDC platform of ... full-service clients.  "nowEDC has long been a preferred ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... "FCPX editors can now reveal ... Final Cut Pro X," said Christina Austin - CEO of Pixel Film Studios. ... Cut Pro X users can now reveal the media of their split screens ...
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... Lake Orion, Clarkston, Michigan (PRWEB) , ... June ... ... direction with respect to fertility once they have been diagnosed with endometriosis. These ... tolerable intercourse but they also require a comprehensive approach that can help for ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
Breaking Medicine News(10 mins):